Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999967 · ClinicalTrials.gov registry record
Stanford-Lucidify EEG Delirium Study
A clinical trial, sponsored by Stanford University.
- Not yet
- Registry status
- 80
- Enrollment target
NCT06999967: Clinical Trial study, sponsored by Stanford University.
NCT06999967 is a clinical trial that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06999967 has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of the CGX/Lucidify EEG system in enabling physicians to detect delirium (confusion) in medically ill patients as early as possible in order to minimize the detrimental effects of delirium. The study will involve collecting EEG data through the CGX EEG system (a Research-grade 2-Channel EEG device) and applying the Lucidify EEG software algorithm to identify indicators and degree of delirium, obtain data regarding the amount and degree of patient's movement and activity throughout the day in order to detail delirium subtype, and obtain data regarding the quality of the sleep as it affects delirium severity and duration. By enhancing early detection, this research aims to improve patient outcomes and inform clinical decision-making.
Primary Outcome
Record and collect EEG brain waves on study subjects using the CGX EEG/Lucidify System to assess EEG features to differentiate between delirium positive and delirium negative patients.
Interventions
- DIAGNOSTIC_TEST Electroencephalogram (EEG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2026-05-30 |
What is known before NCT06999967 opens enrollment
NCT06999967 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Electroencephalogram (EEG) is the first listed.
NCT06999967 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06999967 about?
NCT06999967 is a clinical study titled "Stanford-Lucidify EEG Delirium Study". The purpose of this study is to evaluate the effectiveness of the CGX/Lucidify EEG system in enabling physicians to detect delirium (confusion) in medically ill patients as early as possible in order to minimize the detrimental effects of delirium. The study will involve collecting EEG data through ...
What is the current status of trial NCT06999967?
This trial is currently not yet recruiting. The enrollment target is 80 participants. The study started on 2025-06-01. Estimated completion is 2026-05-30.
What interventions are being tested in trial NCT06999967?
The interventions under investigation include: Electroencephalogram (EEG) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06999967?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI